The US should have a “couple hundred million” doses of a Covid-19 vaccine by start of 2021, Fauci says

MODERNA-9

The Muslim Times has the best collection of articles for the war against Covid 19, especially the vaccines.

Source: CNN

By Jen Christensen

The US should have 100 million doses of one candidate Covid-19 vaccine by the end of the year, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID) and a member of the White House coronavirus task force, said Tuesday.

“Then, by the beginning of 2021, we hope to have a couple hundred million doses,” Fauci said during a live question and answer session with the Journal of the American Medical Association.

Fauci said the first vaccine candidate, made by biotech company Moderna in partnership with NIAID, should go into a final stage of trials in volunteers, known in the industry as Phase III, by mid-summer. Preparations at national and international sites are already under way, he said.

“The real business end of this all will be the Phase III that starts in the first week of July, hopefully, “ Fauci said. “We want to get as many data points as we can.”

Phase III will involve about 30,000 people. The vaccine will be tested in people between the ages of 18 and 55, as well as in the elderly and in people who have underlying health conditions.

“It’s going to be the entire spectrum,” Fauci said.

Fauci said Phase II of the trial started a few days ago. A few hundred volunteers will be involved in that part of the trial.

The plan is to manufacture doses of the vaccine even before it is clear whether the vaccines work, making close to 100 million doses by November or December, Fauci said. That’s so if it does work, it can be deployed quickly.

Scientists should have enough data by November or December to determine if the vaccine works, Fauci said.

Read further

The best of the Muslim Times’ collection for war against Covid 19:

In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.

For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology

For the latest health news from BBC, Please click here

Novavax starting human trial of its vaccine in Australia

Kaiser Permanente launches first coronavirus vaccine trial

Corona Fear’s Cure: Chanting from the Bible and the Quran

Can You Chant from the Bible or the Quran to Bliss and Happiness?

Japanese flu drug ‘clearly effective’ in treating coronavirus, says China

Synthetic antibodies might offer a quick coronavirus treatment

The Four Possible Timelines for Life Returning to Normal

The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic

Coronavirus: TB Vaccination Trial Started in Melbourne, Australia

The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources

All of humanity are intimate neighbors: Coronavirus proves it once again

Praise be to God for the Miracle of Our Immune System

USA: 15-minute coronavirus test is here

Does the Ordinary Soap Kill Coronavirus?

Here’s a list of disinfectants you can use against coronavirus

For the number of cases and epidemiology in each country go to: WorldOMeters

DAILY NEW CASES AND DEATHS IN US, CDC SITE

Categories: The Muslim Times, Vaccine

1 reply

  1. Coronavirus is a monster, a pandemic, a threat to humanity on a global scale.

    Do I overstate the case? Perhaps, but after nearly 375,000 deaths globally, and 6.2 million infections — meaning there will be more deaths to come — I don’t think I overstate the case by much.

    Coronavirus has already tipped the United States into a recession, and most of the rest of the world as well. Airlines are barely flying, restaurants half-open — if they’re lucky — and amusement parks even in countries such as China, which claims to have largely recovered from the epidemic, operate at a fraction of capacity. Before the world economy can recover, we simply must have a vaccine that permits businesses to open back up, full force.

    But here’s the problem with that (for investors). The urgency of the need means that there will be intense pressure upon the companies, that discover COVID-19 vaccines, to distribute them regardless of whether they make a profit — or even give their vaccines away for free. (Witness, for example, Gilead Sciences’ commitment to distribute its first 1.5 million doses of the remdesivir anti-viral drug free of charge).

    And how is a company supposed to make a profit off of that kind of business model?

    The answer, as 5-star Chardan analyst Geulah Livshits explains in her latest note on Moderna (MRNA), could include the ability to use lessons learned from making one vaccine at low or no profit, to the production of other vaccines for a profit.

    Moderna, you see, is working to get U.S. Food and Drug Administration (FDA) approval of its new mRNA vaccine candidate (mRNA-1273) to prevent infection with the novel coronavirus SARS-CoV-2. In so doing, Moderna is perfecting such processes as using DNA plasmid templates, along with enzymes and buffer systems, “to assemble nucleotides into mRNA, which can then be formulated into lipid nanoparticles (LNPs) that can then be filtered, fill-finished into vials, and quality controlled” to produce safe, effective vaccines against COVID-19.

    https://finance.yahoo.com/news/moderna-vaccine-business-could-bigger-165756024.html

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.